Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial Seite 1

09.01.2024 - Phase 2 of the trial aims to recruit 32 patients with HMA-failed MDS and to provide final and optimized dosing for registrational studyCompany is exploring further development opportunities within the bexmarilimab program in hematological cancer ... Seite 1

Related Keywords

Birge Berns , , Chief Medical Officer , Faron Pharmaceuticals Oy Chart , Aron Pharmaceuticals Oy Kurs , Aron Pharmaceuticals Oy Aktie ,